Although age‐related ovarian failure in female mammals cannot be reversed, recent
strategies have focused on improving reproductive capacity with age, and rapamycin is one …

Rapamycin increases lifespan in mice, but whether this represents merely inhibition of lethal
neoplastic diseases, or an overall slowing in multiple aspects of aging is currently unclear …

The ovarian follicle pool size is limited; it decreases with age and following germ cell-
damaging chemo-or radiation therapies. Due to a trend of delaying child-bearing age in the …

Inhibition of the mTOR (mechanistic target of rapamycin) signaling pathway by the FDA-
approved drug rapamycin promotes life span in numerous model organisms and delays age …

Aging is a major risk factor for a large number of disorders and functional impairments.
Therapeutic targeting of the aging process may therefore represent an innovative strategy in …

Caloric restriction (CR) increases the preservation of the ovarian primordial follicular
reserve, which can potentially delay menopause. Rapamycin also increases preservation on …

Prior to 2009 the consensus of scholars was that aging could not be treated or if it could be it
must be a youth factor (eg, growth hormone). Numerous advertised non-scientific …

To see if variations in timing of rapamycin (Rapa), administered to middle aged mice starting
at 20 months, would lead to different survival outcomes, we compared three dosing …

To maintain the normal length of female reproductive life, the majority of primordial follicles
must be maintained in a quiescent state for later use. In this study, we aimed to study the …

Rapamycin, an inhibitor of m TOR kinase, increased median lifespan of genetically
heterogeneous mice by 23%(males) to 26%(females) when tested at a dose threefold higher …